Life Science REIT has successfully completed its IPO, raising gross proceeds of £350m, becoming the first London-listed real estate investment trust focused on UK life science properties.
New ordinary shares were issued at £1 each and the company has made an application for 350m shares to be admitted to AIM. It is expected the dealings will commence in the shares on 19 November, under the tickers LABS. UK Residential REIT contemplates options as it fails to hit target by deadline The company received applications exceeding the maximum £350m size of the issue and, as a result, a scaling-back exercise has been undertaken. Investors in Life Science REIT will have exposure to a diversified portfolio of properties across the UK, with particular focus on the "Golden Tr...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
